Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

ClinicalTrials.gov ID: NCT01681290

Public ClinicalTrials.gov record NCT01681290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects With Mild to Moderate Diabetic Peripheral Neuropathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild to moderate diabetic peripheral neuropathy (DPN).

Study identification

NCT ID: NCT01681290
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Cebix Incorporated; Industry
Enrollment: 250 participants

Conditions and interventions

Conditions

Diabetic Peripheral Neuropathy

Interventions

CBX129801 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2012 (Type not available)
Primary completion: Nov 2014 (Actual)
Completion: Jan 2015 (Actual)
Last update posted: Jan 30, 2015

2012 – 2015

United States locations

U.S. sites: 22
U.S. states: 10
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Escondido	California	92026	—
Not listed	Fresno	California	93720	—
Not listed	Irvine	California	92618	—
Not listed	Los Angeles	California	90036	—
Not listed	San Diego	California	92161	—
Not listed	San Francisco	California	94110	—
Not listed	Torrance	California	90502	—
Not listed	Tustin	California	92780	—
Not listed	Walnut Creek	California	94598	—
Not listed	Atlanta	Georgia	30318	—
Not listed	Decatur	Georgia	30033	—
Not listed	Idaho Falls	Idaho	83404	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Ann Arbor	Michigan	48109	—
Not listed	Butte	Montana	59701	—
Not listed	Omaha	Nebraska	68131	—
Not listed	Las Vegas	Nevada	89102	—
Not listed	New York	New York	10032	—
Not listed	Dallas	Texas	75230	—
Not listed	Houston	Texas	77030	—
Not listed	Houston	Texas	77074	—
Not listed	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01681290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 30, 2015 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01681290 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →